BG100910A - Използване на бисфосфонати за инхибиране на костна резорбция след имплантиране на ортопедична протеза - Google Patents

Използване на бисфосфонати за инхибиране на костна резорбция след имплантиране на ортопедична протеза

Info

Publication number
BG100910A
BG100910A BG100910A BG10091096A BG100910A BG 100910 A BG100910 A BG 100910A BG 100910 A BG100910 A BG 100910A BG 10091096 A BG10091096 A BG 10091096A BG 100910 A BG100910 A BG 100910A
Authority
BG
Bulgaria
Prior art keywords
resartment
inhibitation
bisphosphonates
implantation
bone
Prior art date
Application number
BG100910A
Other languages
English (en)
Other versions
BG63102B1 (bg
Inventor
Ashley Yates
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of BG100910A publication Critical patent/BG100910A/bg
Publication of BG63102B1 publication Critical patent/BG63102B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
  • Dental Preparations (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретението се отнася до метод за лечение и предотвратяване на перипротезна костна загуба чрез прилагане на бисфосфонатен инхибитор на костна резорбция, например алендронат, при пациенти с ортопедично имплантирано средство.
BG100910A 1994-04-21 1996-10-16 Използване на бисфосфонати за инхибиране на костна резорбция след имплантиране на ортопедична протеза BG63102B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/230,670 US5646134A (en) 1994-04-21 1994-04-21 Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
PCT/US1995/004498 WO1995028936A1 (en) 1994-04-21 1995-04-17 Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis

Publications (2)

Publication Number Publication Date
BG100910A true BG100910A (bg) 1998-03-31
BG63102B1 BG63102B1 (bg) 2001-04-30

Family

ID=22866129

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100910A BG63102B1 (bg) 1994-04-21 1996-10-16 Използване на бисфосфонати за инхибиране на костна резорбция след имплантиране на ортопедична протеза

Country Status (29)

Country Link
US (3) US5646134A (bg)
EP (2) EP0756483B1 (bg)
JP (1) JPH09512268A (bg)
CN (1) CN1078073C (bg)
AT (1) ATE236641T1 (bg)
AU (1) AU2374895A (bg)
BG (1) BG63102B1 (bg)
CA (1) CA2188030C (bg)
CO (1) CO4370025A1 (bg)
CZ (1) CZ305596A3 (bg)
DE (1) DE69530293T2 (bg)
DK (1) DK0756483T3 (bg)
DZ (1) DZ1873A1 (bg)
ES (1) ES2194050T3 (bg)
FI (1) FI964213A0 (bg)
HR (1) HRP950239A2 (bg)
HU (1) HUT74911A (bg)
IL (1) IL113361A (bg)
MY (1) MY114265A (bg)
NO (1) NO312124B1 (bg)
NZ (1) NZ284295A (bg)
PL (1) PL318552A1 (bg)
PT (1) PT756483E (bg)
RU (1) RU2161032C2 (bg)
SK (1) SK133396A3 (bg)
TW (1) TW406021B (bg)
WO (1) WO1995028936A1 (bg)
YU (1) YU25295A (bg)
ZA (1) ZA953185B (bg)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
EP0886521B1 (en) * 1996-02-14 2003-05-21 Itzhak Binderman Topical bisphosphonates for prevention of bone resorption
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
EP0998292B1 (en) * 1997-07-22 2001-11-21 Merck & Co., Inc. (a New Jersey corp.) Method for inhibiting bone resorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
IT1296495B1 (it) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
AU756540B2 (en) * 1998-12-04 2003-01-16 Roche Diagnostics Gmbh Use of ibandronate for promoting osseointegration of endoprostheses
AU1798700A (en) 1998-12-25 2000-07-31 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions for treating osseous lesion in multiple myeloma
WO2000064516A1 (en) * 1999-04-22 2000-11-02 Hydromed Sciences A Division Of Gp Strategies Corporation Controlled delivery of bisphosphonates
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
AU781068B2 (en) * 1999-08-19 2005-05-05 Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children), The Drug for treating fractures
WO2002004038A1 (en) * 2000-07-12 2002-01-17 Hopital Orthopedique De La Suisse Romande Active biocoating for bone implant
CH694935A5 (de) * 2000-07-26 2005-09-30 Straumann Holding Ag Oberflaechenmodifizierte Implantate.
AU2001221607A1 (en) 2000-11-20 2002-05-27 Ecole Polytechnique Federale De Lausanne (Epfl) Endosseous implant
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
RU2176519C1 (ru) * 2001-01-29 2001-12-10 Государственное учреждение науки Научно-исследовательский институт травматологии и ортопедии им. Н.Н. Приорова Способ профилактики потери костной ткани вокруг имплантантов при эндопротезировании
RU2284821C2 (ru) * 2001-02-06 2006-10-10 Дзе Ройал Александра Хоспитал Фор Чилдрен Лекарственное средство для лечения остеонекроза и для лечения пациентов с риском развития остеонекроза
PL361909A1 (en) * 2001-02-06 2004-10-04 The Royal Alexandra Hospital For Children A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
EP1383509A4 (en) * 2001-04-03 2005-10-26 Royal Alexandra Hosp Children MEDICAMENT FOR USE IN BONE TRAINING
KR20020080018A (ko) * 2001-04-10 2002-10-23 한국화학연구원 비스포스포네이트 골 흡수억제제의 이식형 서방성제제
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
HUP0402267A3 (en) * 2001-12-21 2007-05-29 Procter & Gamble Method for treatment of bone disorders
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
AU2003221582A1 (en) 2002-05-03 2003-11-17 Millenium Biologix Inc. Connective tissue stimulating peptides
US20040137058A1 (en) * 2002-07-09 2004-07-15 Katdare Ashok V. Effervescent bisphosphonate formulation
ES2561463T3 (es) * 2003-08-21 2016-02-26 Addbio Ab Dispositivo de implante recubierto con bisfosfonato y método para el mismo
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US7674454B2 (en) * 2004-03-06 2010-03-09 Innovata Limited Enzyme-prodrug therapy for prosthetic joint repair
KR100564628B1 (ko) * 2004-06-16 2006-03-28 삼성전자주식회사 스플릿 게이트형 플래쉬 메모리 소자 및 그 제조방법
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
WO2006100527A1 (en) * 2005-03-24 2006-09-28 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Effervescent tablet containing sodium alendronate and related use and process
US20070087052A1 (en) * 2005-10-19 2007-04-19 Katdare Ashok V Effervescent bisphosphonate formulation
FR2904784B1 (fr) * 2006-08-10 2010-09-03 Surfactis Technologies Procede de recouvrement de surfaces metalliques et minerales par de monocouches autoassemblees de composes bisphosphoniques et leurs utilisations
RU2325170C1 (ru) * 2006-12-08 2008-05-27 Федеральное государственное учреждение "Центральный научно-исследовательский институт травматологии и ортопедии им. Н.Н. Приорова Федерального агентства по здравоохранению и социальному развитию" (ФГУ "ЦИТО им. Н.Н. Приорова Росздрава") Биокомпозиционный материал для остеопластики
WO2008116133A1 (en) * 2007-03-21 2008-09-25 Duke University Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
US8183225B2 (en) * 2007-11-08 2012-05-22 New York University Inhibition of bone resorption using medical implants containing adenosine receptor antagonists
PT2473172E (pt) 2009-09-01 2015-06-25 Univ Duke Composições de bisfosfonato e métodos para o tratamento de insuficiência cardíaca
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
ES2716525T3 (es) 2010-12-06 2019-06-13 Effrx Pharmaceuticals Sa Formulaciones de bisfosfonatos efervescentes estables con características de solubilización rápida
US8858979B1 (en) 2011-01-28 2014-10-14 Clemson University Service induced byproducts for localized drug delivery in orthopaedic implants
KR102072250B1 (ko) * 2011-05-27 2020-03-02 아블린쓰 엔.브이. Ｒａｎｋｌ 결합 펩티드를 이용한 골 재흡수 억제
CA2856030A1 (en) 2011-11-16 2013-05-23 Duke University Bisphosphonate compositions and methods for treating and/or reducing cardiac dysfunction
RU2653627C1 (ru) * 2016-11-09 2018-05-11 Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" Способ моделирования асептического аминобисфосфонатного остеонекроза нижней челюсти у лабораторных белых крыс
US12029640B2 (en) 2017-12-07 2024-07-09 Paul V. Fenton, Jr. Method and injection system for bone tissue implant

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
US4753652A (en) * 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
CN1046853C (zh) * 1988-01-20 1999-12-01 山之内制药株式会社 制备药用组合物的方法
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
WO1993024496A1 (en) * 1992-05-29 1993-12-09 Procter & Gamble Pharmaceuticals, Inc. Sulfur-containing phosponate compounds for treating abnormal calcium and phosphate metabolism
CA2151240A1 (en) * 1992-12-23 1994-07-07 Donna T. Whiteford Biophosphonate/estrogen therapy for treating and preventing bone loss
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
FI92465C (fi) * 1993-04-14 1994-11-25 Risto Tapani Lehtinen Menetelmä endo-osteaalisten materiaalien käsittelemiseksi
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration

Also Published As

Publication number Publication date
JPH09512268A (ja) 1997-12-09
RU2161032C2 (ru) 2000-12-27
DK0756483T3 (da) 2003-04-28
HU9602888D0 (en) 1996-12-30
ATE236641T1 (de) 2003-04-15
YU25295A (sh) 1999-09-27
NO964441D0 (no) 1996-10-18
CN1078073C (zh) 2002-01-23
HUT74911A (en) 1997-03-28
FI964213A7 (fi) 1996-10-18
CO4370025A1 (es) 1996-10-07
PL318552A1 (en) 1997-06-23
SK133396A3 (en) 1997-05-07
CA2188030C (en) 2003-07-29
PT756483E (pt) 2003-07-31
CZ305596A3 (en) 1997-06-11
CA2188030A1 (en) 1995-11-02
US5646134A (en) 1997-07-08
DE69530293T2 (de) 2004-02-05
US5972913A (en) 1999-10-26
NO312124B1 (no) 2002-03-25
BG63102B1 (bg) 2001-04-30
EP0756483A1 (en) 1997-02-05
IL113361A (en) 1999-11-30
US5891863A (en) 1999-04-06
WO1995028936A1 (en) 1995-11-02
MY114265A (en) 2002-09-30
FI964213L (fi) 1996-10-18
DZ1873A1 (fr) 2002-02-17
IL113361A0 (en) 1995-07-31
FI964213A0 (fi) 1996-10-18
HRP950239A2 (en) 1997-04-30
NZ284295A (en) 2000-06-23
EP0756483B1 (en) 2003-04-09
ES2194050T3 (es) 2003-11-16
DE69530293D1 (de) 2003-05-15
EP1197213A2 (en) 2002-04-17
TW406021B (en) 2000-09-21
NO964441L (no) 1996-10-18
ZA953185B (en) 1995-12-27
CN1146152A (zh) 1997-03-26
AU2374895A (en) 1995-11-16
EP1197213A3 (en) 2002-09-25

Similar Documents

Publication Publication Date Title
FI971974A0 (fi) Tienopyridiini- tai tienopyrimidiinijohdannaiset ja niiden käyttö
NO952131D0 (no) Fremgangsmåte for behandling av et kirurgisk metallimplantat
PT756483E (pt) Uso de bisfosfonatos para inibir a reabsorcao ossea a seguir a implantacao de proteses ortopedicas
FI955747A7 (fi) Osteosynteesi-apuväline reisiluumurtumien hoitamiseksi
DK1139891T3 (da) Anordning til udvendig fiksering af knoglebrud, især brud på ankelen
ES2064130T3 (es) Utilizacion de droloxifeno para el tratamiento de enfermedades de los huesos.
ATE208625T1 (de) Pflanzenextrakte zur behandlung einer gesteigerten knochenresorption
DK0881908T3 (da) Anvendelse af fiberblastvækstfaktorer til stimulering af knoglevækst
IL138402A0 (en) Heterocyclically substituted amides used as calpain inhibitors
NO952824D0 (no) Sterile gelsammensetninger for sårbehandling
DE69501419D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose enthaltend Xanthohumol
NO965228L (no) Pyridylbisfosfonater for anvendelse som terapeutisk middel
ITVR950078A0 (it) Strumentario per il trattamento di fratture articolari della caviglia
DE69723639D1 (de) Benzothiophenverbindungen, Zubereitungen und Verfahren
UA31298A (uk) Пристрій для лікування переломів щиколоток
BR9303180A (pt) Fixador externo ortopédico proximal de fêmur
AR030757A1 (es) Utilizacion de derivados de la vitamina d como inhibidores de la resorcion osea
UA33331A (uk) Спосіб профілактики гнійно-септичних ускладнень в післяопераційному періоді
ITMI910806A0 (it) Dispositivo di fissazione dinamica endomidollare, particolarmente per il trattamento delle fratture del femore